Jindong Dai

755 total citations
35 papers, 191 citations indexed

About

Jindong Dai is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Molecular Biology. According to data from OpenAlex, Jindong Dai has authored 35 papers receiving a total of 191 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Pulmonary and Respiratory Medicine, 12 papers in Cancer Research and 10 papers in Molecular Biology. Recurrent topics in Jindong Dai's work include Prostate Cancer Treatment and Research (19 papers), Prostate Cancer Diagnosis and Treatment (12 papers) and Renal cell carcinoma treatment (9 papers). Jindong Dai is often cited by papers focused on Prostate Cancer Treatment and Research (19 papers), Prostate Cancer Diagnosis and Treatment (12 papers) and Renal cell carcinoma treatment (9 papers). Jindong Dai collaborates with scholars based in China, United States and Switzerland. Jindong Dai's co-authors include Guangxi Sun, Jinge Zhao, Junru Chen, Pengfei Shen, Sha Zhu, Yuchao Ni, Xudong Zhu, Xingming Zhang, Hao Zeng and Zhipeng Wang and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The FASEB Journal.

In The Last Decade

Jindong Dai

30 papers receiving 190 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jindong Dai China 9 117 58 55 44 29 35 191
Yuchao Ni China 8 118 1.0× 44 0.8× 42 0.8× 40 0.9× 26 0.9× 26 176
Marguerite du Plessis United States 7 199 1.7× 46 0.8× 65 1.2× 63 1.4× 80 2.8× 22 290
Nathalie Leclercq France 9 145 1.2× 108 1.9× 64 1.2× 77 1.8× 39 1.3× 19 268
Ricardo Pereira Mestre Switzerland 8 150 1.3× 36 0.6× 48 0.9× 58 1.3× 13 0.4× 22 214
Hao Zeng China 8 42 0.4× 81 1.4× 51 0.9× 60 1.4× 18 0.6× 20 206
Heikki Seikkula Finland 8 104 0.9× 79 1.4× 28 0.5× 51 1.2× 33 1.1× 30 204
Shuqiu Chen China 9 126 1.1× 217 3.7× 190 3.5× 36 0.8× 50 1.7× 30 375
Mark Bi United States 4 103 0.9× 62 1.1× 53 1.0× 37 0.8× 44 1.5× 5 166
Catarina Silveira Portugal 6 58 0.5× 57 1.0× 44 0.8× 53 1.2× 32 1.1× 13 148
Fabian Rössler Switzerland 6 45 0.4× 64 1.1× 29 0.5× 77 1.8× 52 1.8× 29 171

Countries citing papers authored by Jindong Dai

Since Specialization
Citations

This map shows the geographic impact of Jindong Dai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jindong Dai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jindong Dai more than expected).

Fields of papers citing papers by Jindong Dai

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jindong Dai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jindong Dai. The network helps show where Jindong Dai may publish in the future.

Co-authorship network of co-authors of Jindong Dai

This figure shows the co-authorship network connecting the top 25 collaborators of Jindong Dai. A scholar is included among the top collaborators of Jindong Dai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jindong Dai. Jindong Dai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fu, Na, et al.. (2025). AS-IV inhibits the progression of ovarian cancer by targeting the circ_0124787/miR-6875–3p/IL-1β axis. Biomedicine & Pharmacotherapy. 193. 118681–118681.
2.
3.
Dai, Jindong, Ben He, Yaowen Zhang, et al.. (2024). The survival benefit of metastasectomy for metastatic non-clear cell renal cell carcinoma: a retrospective cohort study. World Journal of Urology. 42(1). 259–259. 1 indexed citations
4.
Zeng, Hong, Mengni Zhang, Yandong Xie, et al.. (2023). Primary renal mucinous adenocarcinoma masquerading as a giant renal cyst: a case report. Frontiers in Oncology. 13. 1129680–1129680. 1 indexed citations
5.
Zhu, Sha, Jiayu Liang, Yuchao Ni, et al.. (2023). Mutations in epigenetic regulator KMT2C detected by liquid biopsy are associated with worse survival in prostate cancer patients. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics. 31(4). 605–614. 5 indexed citations
6.
Chen, Junru, Yaowen Zhang, Xingming Zhang, et al.. (2022). Comparison of Systemic Treatments for Metastatic Castration-Resistant Prostate Cancer After Docetaxel Failure: A Systematic Review and Network Meta-analysis. Frontiers in Pharmacology. 12. 789319–789319. 14 indexed citations
7.
Dai, Jindong, Ben He, Zhihong Liu, Ming Shi, & Pengfei Shen. (2022). Primary melanoma of the bladder: case report and review of the literature. World Journal of Surgical Oncology. 20(1). 287–287. 1 indexed citations
8.
Zhao, Jinge, Guangxi Sun, Junru Chen, et al.. (2022). The therapeutic efficacy of radical prostatectomy and external beam radiation therapy in patients with different pathological patterns of prostate cancer. Asian Journal of Surgery. 46(10). 4178–4185. 1 indexed citations
9.
Zhao, Junjie, Jiayu Liang, Yang Yang, et al.. (2022). Integrated multi-omics analyses reveal that BCAM is associated with epigenetic modification and tumor microenvironment subtypes of clear cell renal cell carcinoma. Clinical Epigenetics. 14(1). 99–99. 5 indexed citations
10.
Dai, Jindong, et al.. (2022). Pulse Drug Delivery Strategy Based on Pharmacokinetic-Pharmacodynamic (PK-PD) Model of Tolerance. SHILAP Revista de lepidopterología.
11.
Zhu, Xudong, Xingming Zhang, Guangxi Sun, et al.. (2021). Efficacy and Safety of Individualized Schedule of Sunitinib by Drug Monitoring in Patients with Metastatic Renal Cell Carcinoma. Cancer Management and Research. Volume 13. 6833–6845. 5 indexed citations
12.
13.
Shen, Pengfei, Guangxi Sun, Peng Zhao, et al.. (2020). MicroRNA-106a suppresses prostate cancer proliferation, migration and invasion by targeting tumor-derived IL-8. Translational Cancer Research. 9(5). 3507–3517. 4 indexed citations
14.
Dai, Jindong, Xingming Zhang, Zhenhua Liu, et al.. (2020). <p>The Prognostic Value of Body Fat Components in Metastasis Renal Cell Carcinoma Patients Treated with TKIs</p>. Cancer Management and Research. Volume 12. 891–903. 5 indexed citations
15.
Wang, Zhipeng, Yuchao Ni, Junru Chen, et al.. (2020). The efficacy and safety of radical prostatectomy and radiotherapy in high-risk prostate cancer: a systematic review and meta-analysis. World Journal of Surgical Oncology. 18(1). 42–42. 32 indexed citations
16.
Dai, Jindong, Xingming Zhang, Jinge Zhao, et al.. (2019). The value of transperineal apical prostate biopsy in predicting urethral/apical margin status after radical prostatectomy. Medicine. 98(43). e17633–e17633. 1 indexed citations
17.
Sun, Guangxi, Xingming Zhang, Zhenhua Liu, et al.. (2019). The Adiponectin-AdipoR1 Axis Mediates Tumor Progression and Tyrosine Kinase Inhibitor Resistance in Metastatic Renal Cell Carcinoma. Neoplasia. 21(9). 921–931. 20 indexed citations
18.
19.
20.
Chen, Junru, Xingming Zhang, Guangxi Sun, et al.. (2018). The effect of additional chemotherapy on high-risk prostate cancer: a systematic review and meta-analysis. OncoTargets and Therapy. Volume 11. 9061–9070. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yuchao Ni Breakdown of academic impact, for papers by Marguerite du Plessis Breakdown of academic impact, for papers by Nathalie Leclercq Breakdown of academic impact, for papers by Ricardo Pereira Mestre Breakdown of academic impact, for papers by Hao Zeng Breakdown of academic impact, for papers by Heikki Seikkula Breakdown of academic impact, for papers by Shuqiu Chen Breakdown of academic impact, for papers by Mark Bi Breakdown of academic impact, for papers by Catarina Silveira Breakdown of academic impact, for papers by Fabian Rössler
Rankless by CCL
2026